A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Abstract Background The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high resp...

Full description

Bibliographic Details
Main Authors: Madelyn Espinosa-Cotton, Elana J. Fertig, Laura P. Stabile, Autumn Gaither-Davis, Julie E. Bauman, Sandra Schmitz, Katherine N. Gibson-Corley, Yinwen Cheng, Isaac J. Jensen, Vladimir P. Badovinac, Douglas Laux, Andrean L. Simons
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Biomarker Research
Subjects:
Cetuximab
Interleukin-1 (IL-1)
Head and neck squamous cell carcinoma (HNSCC)
Biomarker
Online Access:http://link.springer.com/article/10.1186/s40364-019-0164-0

Internet

http://link.springer.com/article/10.1186/s40364-019-0164-0

Similar Items